The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Tumor-induced osteomalacia
Open accessAbstract
Tumor-induced osteomalacia (TIO) is a rare and fascinating paraneoplastic syndrome in which patients present with bone pain, fractures, and muscle weakness. The cause is high blood levels of the recently identified phosphate and vitamin D-regulating hormone, fibroblast growth factor 23 (FGF23). In TIO, FGF23 is secreted by mesenchymal tumors that are usually benign, but are typically very small and difficult to locate. FGF23 acts primarily at the renal tubule and impairs phosphate reabsorption and 1α-hydroxylation of 25-hydroxyvitamin D, leading to hypophosphatemia and low levels of 1,25-dihydroxy vitamin D. A step-wise approach utilizing functional imaging (F-18 fluorodeoxyglucose positron emission tomography and octreotide scintigraphy) followed by anatomical imaging (computed tomography and/or magnetic resonance imaging), and, if needed, selective venous sampling with measurement of FGF23 is usually successful in locating the tumors. For tumors that cannot be located, medical treatment with phosphate supplements and active vitamin D (calcitriol or alphacalcidiol) is usually successful; however, the medical regimen can be cumbersome and associated with complications. This review summarizes the current understanding of the pathophysiology of the disease and provides guidance in evaluating and treating these patients. Novel imaging modalities and medical treatments, which hold promise for the future, are also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Algebraic decay in hierarchical graphs
Garcia, A., Sonnino, G., Malek-Mansour, M.-A., & Baras, F. (1997) · doi:10.1023/a · Cited by 5,187
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Regulation of Fibroblast Growth Factor-23 Signaling by Klotho
Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M.-C., Moe, O. W., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500457200 · Cited by 1,366
Feng, J. Q., Ward, L. M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S. I., Zhang, S., et al. (2006) · Nature Genetics · doi:10.1038/ng1905 · Cited by 1,199 · cited 2×
“Once identified as the cause of ADHR, elevations in serum FGF23 were soon found in TIO (White et al. 2001), X-linked hypophosphatemia (XLH; Jonsson et al. 2003), FD (Riminucci et al. 2003), ADHR (Imel et al. 2007) and autosomalrecessive hypophosphatemic rickets (ARHR; Feng et al. 2006).”
BackgroundFrancis, F., Hennig, S., Korn, B., Reinhardt, R., de Jong, P., Poustka, A., Lehrach, H., Rowe, P. S. N., Goulding, J. N., Summerfield, T., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-130 · Cited by 1,107
Gharib, H., Papini, E., Paschke, R., Duick, D. S., Valcavi, R., Hegedüs, L., Vitti, P., Gharib, H., Papini, E., Paschke, R., et al. (2010) · Endocrine Practice · doi:10.4158/10024.gl · Cited by 1,088
Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020881 · Cited by 914
NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION
Walton, R. J., & Bijvoet, O. L. M. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92736-1 · Cited by 886
The Israel Medical Association journal
(2022) · The Israel Medical Association journal : IMAJ · doi:10.54853/15651088 · Cited by 878
Journal of the Association of Physicians of India
(2023) · Journal of the Association of Physicians of India · doi:10.5005/japi · Cited by 837
J OURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
Kapol, N. (2008) · Cited by 817
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Bergwitz, C., & Jüppner, H. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.111339 · Cited by 741
A common molecular basis for three inherited kidney stone diseases
Lloyd, S. E., Pearce, S. H. S., Fisher, S. E., Steinmeyer, K., Schwappach, B., Scheinman, S. J., Harding, B., Bolino, A., Devoto, M., Goodyer, P., et al. (1996) · Nature · doi:10.1038/379445a0 · Cited by 724
Larsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Yamazaki, Y., Okazaki, R., Shibata, M., Hasegawa, Y., Satoh, K., Tajima, T., Takeuchi, Y., Fujita, T., Nakahara, K., Yamashita, T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021105 · Cited by 671
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting
Riminucci, M., Collins, M. T., Fedarko, N. S., Cherman, N., Corsi, A., White, K. E., Waguespack, S., Gupta, A., Hannon, T., Econs, M. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18399 · Cited by 657
Self-citationTHE AMERICAN JOURNAL OF DISEASES OF CHILDREN
GRULEE, C. G. (1951) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1951.02040030384005 · Cited by 650
Topaz, O., Shurman, D. L., Bergman, R., Indelman, M., Ratajczak, P., Mizrachi, M., Khamaysi, Z., Behar, D., Petronius, D., Friedman, V., et al. (2004) · Nature Genetics · doi:10.1038/ng1358 · Cited by 596
Lorenz-Depiereux, B., Bastepe, M., Benet-Pagès, A., Amyere, M., Wagenstaller, J., Müller-Barth, U., Badenhoop, K., Kaiser, S. M., Rittmaster, R. S., Shlossberg, A. H., et al. (2006) · Nature Genetics · doi:10.1038/ng1868 · Cited by 529
Ferrari, S. L., Bonjour, J.-P., & Rizzoli, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1039 · Cited by 518 · cited 1×
“Physiologic regulation of FGF23 secretion is still being defined, but probably serum phosphorus (Larsson et al. 2003, Ferrari et al. 2005, Nishida et al. 2006, Ito et al. 2007) and/or serum 1,25-vitamin D (Collins et al. 2005) are important in regulating the levels of FGF23.”
BackgroundAn FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
Benet-Pagès, A., Orlik, P., Strom, T. M., & Lorenz-Depiereux, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi034 · Cited by 507
Bergwitz, C., Roslin, N. M., Tieder, M., Loredo-Osti, J. C., Bastepe, M., Abu-Zahra, H., Frappier, D., Burkett, K., Carpenter, T. O., Anderson, D., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499409 · Cited by 493
The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis
Razzaque, M. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.196 · Cited by 448
RICKETS RESISTANT TO VITAMIN D THERAPY
ALBRIGHT, F. (1937) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1937.01980030073005 · Cited by 446
Lorenz-Depiereux, B., Schnabel, D., Tiosano, D., Häusler, G., & Strom, T. M. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.01.006 · Cited by 387
Lorenz-Depiereux, B., Benet-Pages, A., Eckstein, G., Tenenbaum-Rakover, Y., Wagenstaller, J., Tiosano, D., Gershoni-Baruch, R., Albers, N., Lichtner, P., Schnabel, D., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499410 · Cited by 379
Santer, R., Schneppenheim, R., Dombrowski, A., Götze, H., Steinmann, B., & Schaub, J. (1997) · Nature Genetics · doi:10.1038/ng1197-324 · Cited by 335
White, K. E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.497 · Cited by 329
Inhibition of Renal Phosphate Transport by a Tumor Product in a Patient with Oncogenic Osteomalacia
Cai, Q., Hodgson, S. F., Kao, P. C., Lennon, V. A., Klee, G. G., Zinsmiester, A. R., & Kumar, R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302304 · Cited by 322
Wild, D., Schmitt, J. S., Ginj, M., Mäcke, H. R., Bernard, B. F., Krenning, E., de Jong, M., Wenger, S., & Reubi, J.-C. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1255-5 · Cited by 310
Econs, M. J. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.674 · Cited by 305
Levy-Litan, V., Hershkovitz, E., Avizov, L., Leventhal, N., Bercovich, D., Chalifa-Caspi, V., Manor, E., Buriakovsky, S., Hadad, Y., Goding, J., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.01.010 · Cited by 292
Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia
Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, M., Yamashita, T., Fukumoto, S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090509 · Cited by 265
Calcium and phosphate homeostasis: Concerted interplay of new regulators
Renkema, K. Y., Alexander, R. T., Bindels, R. J., & Hoenderop, J. G. (2008) · Annals of Medicine · doi:10.1080/07853890701689645 · Cited by 263 · cited 2×
“Phosphate is vital to normal physiologic functioning; it plays a role in intracellular signaling, membrane function, energy metabolism, and bone mineralization (Sommer et al. 2007, Renkema et al. 2008).”
BackgroundJan de Beur, S. M. (2005) · JAMA · doi:10.1001/jama.294.10.1260 · Cited by 250
Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men
Nishida, Y., Taketani, Y., Yamanaka-Okumura, H., Imamura, F., Taniguchi, A., Sato, T., Shuto, E., Nashiki, K., Arai, H., Yamamoto, H., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5002000 · Cited by 243
Drug-induced Fanconi's syndrome
Izzedine, H., Launay-Vacher, V., Isnard-Bagnis, C., & Deray, G. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50037 · Cited by 238
Octreotide Therapy for Tumor-Induced Osteomalacia
Seufert, J., Ebert, K., Müller, J., Eulert, J., Hendrich, C., Werner, E., Schütze, N., Schulz, G., Kenn, W., Richtmann, H., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010839 · Cited by 234
Initial FGF23-Mediated Signaling Occurs in the Distal Convoluted Tubule
Farrow, E. G., Davis, S. I., Summers, L. J., & White, K. E. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070783 · Cited by 232
Tumor-Induced Osteomalacia -- Unveiling a New Hormone
Econs, M. J., & Drezner, M. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302310 · Cited by 226
Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia
Imel, E. A., Peacock, M., Pitukcheewanont, P., Heller, H. J., Ward, L. M., Shulman, D., Kassem, M., Rackoff, P., Zimering, M., Dalkin, A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2105 · Cited by 226
Nesbitt, T., Coffman, T. M., Griffiths, R., & Drezner, M. K. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115735 · Cited by 219
Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism
De Beur, S. M. J., Finnegan, R. B., Vassiliadis, J., Cook, B., Barberio, D., Estes, S., Manavalan, P., Petroziello, J., Madden, S. L., Cho, J. Y., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1102 · Cited by 212
Endo, I., Fukumoto, S., Ozono, K., Namba, N., Tanaka, H., Inoue, D., Minagawa, M., Sugimoto, T., Yamauchi, M., Michigami, T., et al. (2008) · Bone · doi:10.1016/j.bone.2008.02.014 · Cited by 209
Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice
Dr. Meyer, R. A., Meyer, M. H., & Gray, R. W. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040407 · Cited by 209
Wild, D., Mäcke, H. R., Waser, B., Reubi, J. C., Ginj, M., Rasch, H., Müller-Brand, J., & Hofmann, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1697-4 · Cited by 192
Collins, M. T., Chebli, C., Jones, J., Kushner, H., Consugar, M., Rinaldo, P., Wientroub, S., Bianco, P., & Robey, P. G. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.806 · Cited by 189
Self-citationRenal Tubular Reabsorption of Phosphate (TmP/GFR): Indications and Interpretation
Payne, R. B. (1998) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456329803500203 · Cited by 184
FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets
Imel, E. A., Hui, S. L., & Ecibs, M. J. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070107 · Cited by 182
White, K. E., Larsson, T. E., & Econs, M. J. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0019 · Cited by 178
Takeuchi, Y., Suzuki, H., Ogura, S., Imai, R., Yamazaki, Y., Yamashita, T., Miyamoto, Y., Okazaki, H., Nakamura, K., Nakahara, K., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0406 · Cited by 172
FGF-23 Is Elevated by Chronic Hyperphosphatemia
Gupta, A., Winer, K., Econs, M. J., Marx, S. J., & Collins, M. T. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0724 · Cited by 168
Self-citationCinacalcet in the Management of Tumor-Induced Osteomalacia
Geller, J. L., Khosravi, A., Kelly, M. H., Riminucci, M., Adams, J. S., & Collins, M. T. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070304 · Cited by 149
Self-citationDetermination of the Elimination Half-Life of Fibroblast Growth Factor-23
Khosravi, A., Peck, C. M. C., Kelly, M. H., Chang, R., Royal, R. E., Sherry, R. M., Wodajo, F. M., Fedarko, N. S., & Collins, M. T. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2865 · Cited by 147
Self-citationIntronic Deletions in theSLC34A3Gene Cause Hereditary Hypophosphatemic Rickets with Hypercalciuria
Ichikawa, S., Sorenson, A. H., Imel, E. A., Friedman, N. E., Gertner, J. M., & Econs, M. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2840 · Cited by 139
Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans
Ito, N., Fukumoto, S., Takeuchi, Y., Takeda, S., Suzuki, H., Yamashita, T., & Fujita, T. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0779-3 · Cited by 138
Taketani, Y., Segawa, H., Chikamori, M., Morita, K., Tanaka, K., Kido, S., Yamamoto, H., Iemori, Y., Tatsumi, S., Tsugawa, N., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14575 · Cited by 138
TESTS OF PHOSPHATE REABSORPTION
Kenny, A. P., & Glen, A. C. A. (1973) · The Lancet · doi:10.1016/s0140-6736(73)93112-7 · Cited by 127
Drezner, M. K. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010006811394 · Cited by 126
Selective venous catheterization for the localization of phosphaturic mesenchymal tumors
Andreopoulou, P., Dumitrescu, C. E., Kelly, M. H., Brillante, B. A., Peck, C. M. C., Wodajo, F. M., Chang, R., & Collins, M. T. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.316 · Cited by 125
Self-citationMiyauchi, A., Fukase, M., Tsutsumi, M., et al. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-1-46 · Cited by 120
Frishberg, Y., Topaz, O., Bergman, R., Behar, D. M., Fisher, D., Gordon, D., Richard, G., & Sprecher, E. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0610-8 · Cited by 116
Strontium Induced Rickets: Metabolic Basis
Omdahl, J. L., & DeLuca, H. F. (1971) · Science · doi:10.1126/science.174.4012.949 · Cited by 115
Oncogenic osteomalacia: evidence for a humoral phosphaturic factor.
Wilkins, G. E., Granleese, S. R., Hegele, R. G., et al. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.5.7745010 · Cited by 114
Dupond, J. L., Mahammedi, H., Prié, D., Collin, F., Gil, H., Blagosklonov, O., Ricbourg, B., MÉAUX-RUAULT, N., & Kantelip, B. M. (2005) · Bone · doi:10.1016/j.bone.2005.01.001 · Cited by 114
Aono, Y., Hasegawa, H., Yamazaki, Y., Shimada, T., Fujita, T., Yamashita, T., & Fukumoto, S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.275 · Cited by 109
Fibroblast Growth Factor-23 Is Regulated by 1α,25-Dihydroxyvitamin D
Collins, M. T., Lindsay, J. R., Jain, A., Kelly, M. H., Peck, C. M. C., Weinstein, L. S., Liu, J., Fedarko, N. S., & Winer, K. K. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050718 · Cited by 104
Self-citationFibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia
Nelson, A. E., Clifton-Bligh, R. J., Mirams, M., Gill, A. J., Au, A. Y. M., Clarkson, A., Jüppner, H., Ruff, S. J., Stalley, P., Scolyer, R. A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021919 · Cited by 97
Direct Measurement of TP/GFR: A Simple and Reliable Parameter of Renal Phosphate Handling
Stark, H., Eisenstein, B., Tieder, M., Rachmel, A., & Alpert, G. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000184216 · Cited by 91
Hypophosphataemic Osteomalacia in Fibrous Dysplasia
Dent, C. E., & Gertner, J. M. (1976) · QJM · doi:10.1093/oxfordjournals.qjmed.a067471 · Cited by 88
Barth, J. H., Jones, R. G., & Payne, R. B. (2000) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/0004563001901371 · Cited by 83
The phosphatonins and the regulation of phosphate transport and vitamin D metabolism
Sommer, S. L., Berndt, T. J., Craig, T. A., & Kumar, R. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.11.010 · Cited by 74
Ward, L. M., Rauch, F., White, K. E., Filler, G., Matzinger, M. A., Letts, M., Travers, R., Econs, M. J., & Glorieux, F. H. (2004) · Bone · doi:10.1016/j.bone.2003.12.025 · Cited by 67
Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling
van Boekel, G., Ruinemans‐Koerts, J., Joosten, F. B. M., Dijkhuizen, P. A., van Sorge, A., & de Boer, H. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0779 · Cited by 61
Dumitrescu, C. E., Kelly, M. H., Khosravi, A., Hart, T. C., Brahim, J. S., White, K. E., Farrow, E., Nathan, M. H., Murphey, M. D., & Collins, M. T. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0775-z · Cited by 54
Self-citationHodgson, S. F., Clarke, B. L., Tebben, P. J., Mullan, B. P., Cooney, W. P., & Shives, T. C. (2006) · Endocrine Practice · doi:10.4158/ep.12.1.35 · Cited by 47
Hereditary Renal Tubular Disorders
Chadha, V., & Alon, U. S. (2009) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2009.03.013 · Cited by 44
Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia
Toyosawa, S., Tomita, Y., Kishino, M., Hashimoto, J., Ueda, T., Tsujimura, T., Aozasa, K., Ijuhin, N., & Komori, T. (2004) · Modern Pathology · doi:10.1038/modpathol.3800084 · Cited by 42
Nasu, T., Kurisu, S., Matsuno, S., Tatsumi, K., Kakimoto, T., Kobayashi, M., Nakano, Y., Wakasaki, H., Furuta, H., Nishi, M., et al. (2008) · Internal Medicine · doi:10.2169/internalmedicine.47.0745 · Cited by 42
Hannan, F. M., Athanasou, N. A., Teh, J. L., Gibbons, C. L. M. H., Shine, B. S. F., & Thakker, R. V. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0485 · Cited by 38
Effects of Tumor-Induced Osteomalacia on the Bone Mineralization Process
Nawrot-Wawrzyniak, K., Varga, F., Nader, A., Roschger, P., Sieghart, S., Zwettler, E., Roetzer, K. M., Lang, S., Weinkamer, R., Klaushofer, K., et al. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9216-z · Cited by 35
Peters, K. B., McLendon, R. E., Morse, M. A., & Vredenburgh, J. J. (2010) · Case Reports in Oncology · doi:10.1159/000307468 · Cited by 30
Oncogenic Osteomalacia in a Case with a Maxillary Sinus Mesenchymal Tumor
Koriyama, N., Nakazaki, M., Tei, C., Nishimoto, K., Kurono, Y., Kodama, T., & Yoshida, H. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200609000-00010 · Cited by 27
Elston, M. S., Stewart, I. J., Clifton-Bligh, R. J., & Conaglen, J. V. (2006) · Bone · doi:10.1016/j.bone.2006.07.027 · Cited by 27
Oncogenic Osteomalacia Caused by a Phosphaturic Mesenchymal Tumor of the Oral Cavity
Yang, I. M., Park, Y. K., Hyun, Y. J., Kim, D. Y., Woo, J., Kim, S. W., Kim, J., Kim, Y. S., & Choi, Y. K. (1997) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.1997.12.1.89 · Cited by 27
Habra, M. A., Jiménez, C., Huang, S.-C. E., Cote, G. J., Murphy, W. A., Gagel, R. F., & Hoff, A. O. (2008) · Endocrine Practice · doi:10.4158/ep.14.9.1108 · Cited by 25
Misdiagnosis of Conversion Disorders
Teasell, R. W., & Shapiro, A. P. (2002) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-200203000-00015 · Cited by 24
Friedlaender, M. M., Wald, H., Dranitzki-Elhalel, M., Zajicek, H. K., Levi, M., & Popovtzer, M. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.3.f428 · Cited by 22
Fibroblast growth factor 23 mediates the phosphaturic actions of cadmium
Aranami, F., Segawa, H., Furutani, J., Kuwahara, S., Tominaga, R., Hanabusa, E., Tatsumi, S., Kido, S., Ito, M., & Miyamoto, K. (2010) · The Journal of Medical Investigation · doi:10.2152/jmi.57.95 · Cited by 20
Diffuse pain, hypophosphatemia, and a subcutaneous nodule
DeWitt, C. A., Collins, M. T., & Cowen, E. W. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.05.010 · Cited by 13
Self-citationWoznowski, M., Quack, I., Stegbauer, J., Rump, L. C., Schieren, G., & Buchner, N. (2008) · Clinical Nephrology · doi:10.5414/cnp70431 · Cited by 13
Oncogenic osteomalacia: Muscular weakness and multiple fractures
Ladha, S. S., WHITAKER, M. D., & Bosch, E. P. (2006) · Neurology · doi:10.1212/01.wnl.0000225057.56863.33 · Cited by 7
Szumera‐Ciećkiewicz, A., Ptaszyński, K., Pawełas, A., & Rutkowski, P. L. (2009) · PubMed · Cited by 4
Cited by
Minisola, S., Peacock, M., Fukumoto, S., Cipriani, C., Pepe, J., Tella, S. H., & Collins, M. T. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.44 · Cited by 290
Self-citationFGF23 and its role in X-linked hypophosphatemia-related morbidity
Beck-Nielsen, S. S., Mughal, Z., Haffner, D., Nilsson, O., Levtchenko, E., Ariceta, G., de Lucas Collantes, C., Schnabel, D., Jandhyala, R., & Mäkitie, O. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1014-8 · Cited by 278
Metadata
- Authors
- Chong, W. H., Molinolo, A. A., Chen, C. C., & Collins, M. T.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2011-04-13
- Volume
- 18
- Issue
- 3
- Pages
- R53-R77
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2108513850
- Cited by
- 429
- References
- 95
- FWCI
- 17.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.